Under the radar investment opportunities aren’t necessarily rare but rather are hard to find. And one unpolished gem could be Agentix, a company estimated to have between 200,000 and 1,500,000 shares in its public float and is nearing, at least we believe, commercialization of a comprehensive suite of health solutions for patients and consumers. In fact, an 8K filed last Friday makes the stock more exciting and shows that AGTX is indeed on the move.

In that announcement, AGTX confirmed that on May 21, 2021, it received notice of effectiveness of a certain License Agreement dated May 10, 20201, between its wholly owned subsidiary, Applied BioPharma LLC, and National Health Research Institutes, a Taiwan, Republic of China, entity. According to the filing, AGTX purchased a worldwide, terminable, royalty-bearing, exclusive license for the technology and patent rights for all products related to pyrazole compounds to treat Type 2 diabetes, obesity, and fatty liver disease. 

This technology is a peripherally restricted cannabinoid receptor 1 antagonist that has successfully completed preliminary pre-clinical and in vivo testing requirements for advancement into Phase I clinical trials. This deal can be significant for AGTX near and long term.

Indeed, investors should remain anxious ahead of the details on this new licensing agreement. However, keep in mind that Agentix is already developing synthetic agonists, inverse agonists, and antagonists, which modulate the endocannabinoid system (ECS). The ECS is a network of G-protein-coupled receptors (GPCRs) that help regulate various metabolic and neurotransmission functions. By the way, that market may offer a golden opportunity to the company, noting that over 134 drugs approved worldwide currently target GPCR applications. Better news for Agentix is that the market is proven, with sales of these specific drugs generating several billion dollars annually in revenues. 

Read the complete article at www.digitaljournal.com.

For more information: